Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Combination

A technology of compounds and solvates, applied in the field of treating cancer in mammals, can solve the problem of low frequency

Inactive Publication Date: 2012-09-12
GLAXO SMITHKLINE LLC
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Ultimately, the pathway can be genetically activated downstream of PI3K by DNA amplification or mutation of AKT; however, these genetic events occur with low frequency in human cancers

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination
  • Combination
  • Combination

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0102] Preparation of MEK inhibitors

[0103] MEK inhibitors suitable for use in the combinations according to the invention, in particular

[0104] N-{3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4 ,6,7-Tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl}acetamide dimethyl sulfoxide

[0105]

[0106] It can be prepared according to International Patent Publication WO2005 / 121142.

[0107] PI3K inhibitors suitable for use in the combinations of the invention, in particular

[0108] 2,4-Difluoro-N-{2-(methoxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridyl}benzenesulfonamide

[0109]

[0110] It can be prepared according to International Patent Publication No. WO08 / 144463 (Example 345).

[0111] Compound A described in the experimental part refers to N-{3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2, dimethylsulfoxide solvate of 4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl}acetamide.

[0112] In v...

Embodiment 1

[0222] Example 1 - Capsule Composition

[0223] Oral dosage forms for administering the combinations of the invention are prepared by filling standard two-part hard gelatin capsules with the ingredients in the proportions shown in Table I below.

[0224] Table I

[0225]

[0226]

Embodiment 2

[0227] Example 2 - Capsule Composition

[0228] Oral dosage forms for administering one of the compounds of the invention are prepared by filling standard two-part hard gelatin capsules with the ingredients in the proportions shown in Table II below.

[0229] Table II

[0230]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a method of treating cancer in a mammal and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a novel combination comprising the MEK inhibitor: N -{3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d / ]pyrimidin-1 (2H)-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, and the PI3 kinase inhibitor: 2,4-difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same, and methods of using such combinations in the treatment of cancer.

Description

technical field [0001] The present invention relates to methods of treating cancer in mammals, and to combinations useful in such treatment. Specifically, the method involves the inclusion of the MEK inhibitor: N-{3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2, 4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl}acetamide, or its pharmaceutically acceptable salt or solvent compounds, and PI3K inhibitors: 2,4-difluoro-N-{2-(methoxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridyl} Novel combinations of benzenesulfonamides or pharmaceutically acceptable salts thereof, pharmaceutical compositions containing the combinations, and methods of using the combinations in the treatment of cancer. Background of the invention [0002] Effective treatment of hyperproliferative diseases, including cancer, has long been a goal of the field of oncology. In general, cancers arise from aberrations in the normal processes that control cell division, differenti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/505
CPCC07D401/14C07D471/04A61P35/00A61P43/00A61K31/519A61K31/505A61K31/501
Inventor K.R.奥格K.E.巴克曼T.M.吉尔默小詹姆斯.G.格雷杰J.D.格雷肖克S.拉奎尔L.刘S.R.莫里斯
Owner GLAXO SMITHKLINE LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com